More dialysis patients are receiving red blood cell transfusions following changes in the labeling of erythropoiesis-stimulating agents and new Medicare reimbursement practices involving end-stage renal disease, according to a study presented at a clinical meeting of the National Kidney Foundation. Researchers reviewed data on 42,790 dialysis patients and found an overall increase from 2007 to 2012. The rise has been steeper among Medicare beneficiaries than among those with private insurance since the 2011 reimbursement change.

Related Summaries